Kender Richard N
Known title: DirectorCIK: 0001381205
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
Transaction History
| LGVN | ▲ Buy | Grant | 17,000 | $0 | 7/15/2025 | View on chart |
| BCYC | ▲ Buy | Grant | 6,250 | $0 | 1/2/2025 | View on chart |
| LGVN | ▲ Buy | Grant | 16,000 | $23K | 5/10/2024 | View on chart |
| BCYC | ▲ Buy | Grant | 6,000 | $0 | 1/2/2024 | View on chart |
| BCYC | ▲ Buy | Grant | 5,750 | $0 | 1/3/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 63,492 | $200K | 7/5/2022 | View on chart |
| BCYC | ▲ Buy | Grant | 5,000 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.